Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT ID: NCT05278208
Last Updated: 2025-10-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
65 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-11-21
Study Completion Date
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \</=39 years (Phase II) to test its safety and efficacy, respectively.
Funding Source - FDA OOPD (grant number FD-R-0532-01)
Funding Source - FDA OOPD (grant number FD-R-0532-01)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NCT03971461
Meningioma
ACTIVE_NOT_RECRUITING
PHASE2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
NCT04082520
Grade 1 Meningioma
Grade 2 Meningioma
Grade 3 Meningioma
+2 more
RECRUITING
PHASE2
RTA 744 Injection in Patients With Leptomeningeal Disease
NCT00512460
Neoplastic Meningitis
Solid Tumor
Lymphoma
+2 more
TERMINATED
PHASE1
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
NCT04997317
Meningioma
RECRUITING
PHASE1/PHASE2
177Lu-DOTATATE for Recurrent Meningioma
NCT06326190
Recurrent Meningioma
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Somatostatin receptors regulate cell growth through downstream modulation of both proliferation and apoptosis signaling pathways, and thus represent a potential therapeutic target. Lutathera (Lutetium \[Lu\]177 Dotatate) is a radionuclide therapy which binds type-2A somatostatin receptors (SST2A) and has recently gained FDA approval for the treatment of adult gastroenteropancreatic neuroendocrine tumors expressing SST2A.
High SST2A expression has been consistently observed in medulloblastoma and other embryonal tumors (75-100% of cases) as well as in some HGGs and anaplastic ependymomas (13-80%), with corresponding uptake on radiolabeled somatostatin receptor nuclear imaging (e.g. DOTATATE PET).
Emerging data has demonstrated treatment response (disease stabilization or regression) to somatostatin receptor-targeted therapy in children and young adults with relapsed medulloblastoma, HGG, meningioma, and brain metastases of neuroendocrine tumors, suggesting sufficient CNS penetration to achieve therapeutic benefit.
The proposed Phase I-II study will investigate the safety and efficacy of Lutathera treatment in patients whose tumors demonstrate uptake on DOTATATE PET (functional evidence of SST2A expression). In both Phase cohorts, Lutathera will be administered as an intravenous infusion on day 1 of each 8-week cycle for up to 4 cycles.
Phase I: (4 to \<12 years) To determine the safety, define the dose-limiting toxicities, and establish the maximally tolerated dose (MTD)/ recommended Phase II dose (RP2D) of Lutathera in this patient population. The first cycle (first 8 weeks) will be used as the dose-limiting toxicity (DLT) observation period. The starting dose will be dose level 1, 200 mCi\*(body surface area \[BSA\]/1.73m2), which corresponds to the BSA-adjusted FDA approved adult dosing of Lutathera (200 mCi every 8 weeks). Once the MTD/RP2D is established, an efficacy expansion cohort of up to 10 patients will be opened to determine the preliminary efficacy of the MTD/RP2D of Lutathera in this cohort.
Phase II: (12 to \</=39 years) Enroll patients at the recommended adult dose of 200 mCi every 8 weeks to determine the anti-tumor activity of Lutathera at this dosing in this population. Response will be assessed on imaging (brain and/or spine MRI and DOTATATE PET) following every cycle or every other cycle.
High SST2A expression has been consistently observed in medulloblastoma and other embryonal tumors (75-100% of cases) as well as in some HGGs and anaplastic ependymomas (13-80%), with corresponding uptake on radiolabeled somatostatin receptor nuclear imaging (e.g. DOTATATE PET).
Emerging data has demonstrated treatment response (disease stabilization or regression) to somatostatin receptor-targeted therapy in children and young adults with relapsed medulloblastoma, HGG, meningioma, and brain metastases of neuroendocrine tumors, suggesting sufficient CNS penetration to achieve therapeutic benefit.
The proposed Phase I-II study will investigate the safety and efficacy of Lutathera treatment in patients whose tumors demonstrate uptake on DOTATATE PET (functional evidence of SST2A expression). In both Phase cohorts, Lutathera will be administered as an intravenous infusion on day 1 of each 8-week cycle for up to 4 cycles.
Phase I: (4 to \<12 years) To determine the safety, define the dose-limiting toxicities, and establish the maximally tolerated dose (MTD)/ recommended Phase II dose (RP2D) of Lutathera in this patient population. The first cycle (first 8 weeks) will be used as the dose-limiting toxicity (DLT) observation period. The starting dose will be dose level 1, 200 mCi\*(body surface area \[BSA\]/1.73m2), which corresponds to the BSA-adjusted FDA approved adult dosing of Lutathera (200 mCi every 8 weeks). Once the MTD/RP2D is established, an efficacy expansion cohort of up to 10 patients will be opened to determine the preliminary efficacy of the MTD/RP2D of Lutathera in this cohort.
Phase II: (12 to \</=39 years) Enroll patients at the recommended adult dose of 200 mCi every 8 weeks to determine the anti-tumor activity of Lutathera at this dosing in this population. Response will be assessed on imaging (brain and/or spine MRI and DOTATATE PET) following every cycle or every other cycle.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
High Grade Glioma
Meningioma
Embryonal Tumor
Medulloblastoma
Anaplastic Ependymoma
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Malignant Glioma
Recurrent Medulloblastoma
Recurrent Primary Central Nervous System Neoplasm
Refractory Diffuse Intrinsic Pontine Glioma
Refractory Malignant Glioma
Refractory Medulloblastoma
Refractory Primary Central Nervous System Neoplasm
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Phase I (4 to \<12 yrs) Lutathera (maximum dose of 200 mCi) once every 8 weeks (one cycle) for 4 cycles.
Level 0: 150 mCi\*(BSA/1.73m2). Level 1#: 200 mCi\*(BSA/1.73m2). Level 2: 250 mCi\*(BSA/1.73m2).
#starting dose
Phase II (12 to \</=39 years) RP2D 200 mCi once every 8 weeks
Level 0: 150 mCi\*(BSA/1.73m2). Level 1#: 200 mCi\*(BSA/1.73m2). Level 2: 250 mCi\*(BSA/1.73m2).
#starting dose
Phase II (12 to \</=39 years) RP2D 200 mCi once every 8 weeks
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase I-II
Pediatric patients (4 to \<12 years, Phase I) and adolescent and young adult patients (12 to \</=39 years, Phase II) with recurrent/progressive high-grade central nervous system tumors and meningiomas that express SST2A and demonstrate uptake on DOTATATE PET will receive Lutathera once every 8 weeks (1 cycle) for a total of 4 doses over 8 months
Phase I starting dose will be 200 mCi\*(BSA/1.73m2), corresponding to the BSA-adjusted FDA approved adult Lutathera dosing. The first cycle will be used as the DLT period. Once MTD/RP2D is established, an efficacy expansion cohort of up to 10 patients will be opened to determine the preliminary efficacy of MTD/RP2D of Lutathera
Phase II patients will receive the adult RP2D of 200 mCi every 8 weeks to determine the anti-tumor activity of Lutathera in this patient population, through evaluation of 6-month PFS as the primary efficacy endpoint. Response will be assessed on imaging (brain/spine MRI and DOTATATE PET) following every 1-2 cycles.
Group Type
EXPERIMENTAL
LUTATHERA® (Lutetium Lu 177 dotatate)
Intervention Type
DRUG
Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LUTATHERA® (Lutetium Lu 177 dotatate)
Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Lutathera
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3.1 Uptake on \[68Ga\]Ga-DOTATATE PET Patients must have uptake on DOTATATE PET/CT in at least one tumor lesion (corresponding to known disease) equivalent to a Krenning score ≥2 (confirmed by central radiology review).
3.2 Prior Therapy Patients must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy, radiotherapy, or any other treatment modality prior to entering this study.
3.3 Chemotherapy Patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea.
3.4 Investigational/Biologic Agent
●Biologic or investigational agent (anti-neoplastic): Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment.
For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
●Monoclonal Antibodies and agents with known prolonged half-lives: Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the agent ≥ 28 days prior to study enrollment.
3.5 Radiation
Patients must have had their last fraction of:
* Craniospinal irradiation or total body irradiation or radiation to \> 50% of pelvis \> 3 months prior to enrollment.
* Focal irradiation \> 4 weeks prior to enrollment
3.6 Stem Cell Transplant
Patient must be:
* ≥ 6 months since allogeneic stem cell transplant prior to enrollment with no evidence of active graft vs. host disease
* ≥ 3 months since autologous stem cell transplant prior to enrollment
3.7 Growth Factors Patients must be off all colony-forming growth factor(s) for at least 1 week prior to enrollment (e.g. filgrastim, sargramostim or erythropoietin). Two weeks must have elapsed if patients received long-acting formulations.
3.8 Somatostatin analogs Patients must be off long-acting somatostatin analogs for at least 4 weeks and off short-acting somastatin analogs (i.e., octreotide) for at least 24 hours.
3.9 Neurologic Status
* Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment, documented by a detailed neurological exam.
* Patients with seizure disorders may be enrolled if seizures are well controlled.
3.10 Performance Status Karnofsky Performance Scale (KPS for \> 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within two weeks of enrollment must be ≥ 50. Patients who are unable to walk because of neurologic deficits, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
3.11 Organ Function
Patients must have adequate organ and marrow function, both for eligibility for enrollment, and to begin each subsequent cycle of Lutathera, as defined below:
* Adequate Bone Marrow Function as defined as:
* Absolute neutrophil count ≥ 1.0 x 109 cells/ L
* Platelets ≥100 x 109 cells/ L (unsupported, defined as no platelet transfusion within 7 days)
* Hemoglobin ≥8 g/dl (may receive transfusions)
* Adequate Renal Function as defined as:
* Creatinine clearance or radioisotope GFR \>70mL/min/1.73m2 OR
* A serum creatinine based on (Schwartz et al. J. Peds, 106:522, 1985) age/gender as follows:
1 to \< 2 years: maximum serum creatinine 0.6 mg/dL for males and females. 2 to \< 6 years: maximum serum creatinine 0.8 mg/dL for males and females. 6 to \< 10 years: maximum serum creatinine 1.0 mg/dL for males and females. 10 to \< 13 years: maximum serum creatinine 1.2 mg/dL for males and females. 13 to \< 16 years: maximum serum creatinine 1.5 mg/dL for males and 1.4 mg/dL for females.
≥ 16 years: maximum serum creatinine 1.7 mg/dL for males and 1.4 mg/dL for females.
* Adequate Liver Function as defined as:
* Total bilirubin ≤ 3 times institutional upper limit of normal (ULN) for age
* AST(SGOT)/ALT(SGPT) ≤ 3 times institutional ULN
* Serum albumin ≥ 2g/dL
* Coagulation parameters: INR \<1.5 times ULN and aPTT \<1.5 times ULN unless patients are receiving therapeutic anticoagulation which affects these parameters
* Adequate Cardiac Function as defined as:
* Ejection fraction of ≥ 55% by echocardiogram
* Serum electrolytes (Sodium, Potassium, Chloride) within institutional limits of normal (patients can be on enteral supplementation)
3.12 Corticosteroids Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment, with a maximum dexamethasone dose of 2.5mg/m2/day.
3.13 Pregnancy Status Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
3.14 Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for at least 7 months after drug cessation in females of childbearing potential and for at least 4 months after drug cessation in males of child fathering potential.
3.15 Informed Consent The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.
3.2 Prior Therapy Patients must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy, radiotherapy, or any other treatment modality prior to entering this study.
3.3 Chemotherapy Patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea.
3.4 Investigational/Biologic Agent
●Biologic or investigational agent (anti-neoplastic): Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment.
For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
●Monoclonal Antibodies and agents with known prolonged half-lives: Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the agent ≥ 28 days prior to study enrollment.
3.5 Radiation
Patients must have had their last fraction of:
* Craniospinal irradiation or total body irradiation or radiation to \> 50% of pelvis \> 3 months prior to enrollment.
* Focal irradiation \> 4 weeks prior to enrollment
3.6 Stem Cell Transplant
Patient must be:
* ≥ 6 months since allogeneic stem cell transplant prior to enrollment with no evidence of active graft vs. host disease
* ≥ 3 months since autologous stem cell transplant prior to enrollment
3.7 Growth Factors Patients must be off all colony-forming growth factor(s) for at least 1 week prior to enrollment (e.g. filgrastim, sargramostim or erythropoietin). Two weeks must have elapsed if patients received long-acting formulations.
3.8 Somatostatin analogs Patients must be off long-acting somatostatin analogs for at least 4 weeks and off short-acting somastatin analogs (i.e., octreotide) for at least 24 hours.
3.9 Neurologic Status
* Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment, documented by a detailed neurological exam.
* Patients with seizure disorders may be enrolled if seizures are well controlled.
3.10 Performance Status Karnofsky Performance Scale (KPS for \> 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within two weeks of enrollment must be ≥ 50. Patients who are unable to walk because of neurologic deficits, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
3.11 Organ Function
Patients must have adequate organ and marrow function, both for eligibility for enrollment, and to begin each subsequent cycle of Lutathera, as defined below:
* Adequate Bone Marrow Function as defined as:
* Absolute neutrophil count ≥ 1.0 x 109 cells/ L
* Platelets ≥100 x 109 cells/ L (unsupported, defined as no platelet transfusion within 7 days)
* Hemoglobin ≥8 g/dl (may receive transfusions)
* Adequate Renal Function as defined as:
* Creatinine clearance or radioisotope GFR \>70mL/min/1.73m2 OR
* A serum creatinine based on (Schwartz et al. J. Peds, 106:522, 1985) age/gender as follows:
1 to \< 2 years: maximum serum creatinine 0.6 mg/dL for males and females. 2 to \< 6 years: maximum serum creatinine 0.8 mg/dL for males and females. 6 to \< 10 years: maximum serum creatinine 1.0 mg/dL for males and females. 10 to \< 13 years: maximum serum creatinine 1.2 mg/dL for males and females. 13 to \< 16 years: maximum serum creatinine 1.5 mg/dL for males and 1.4 mg/dL for females.
≥ 16 years: maximum serum creatinine 1.7 mg/dL for males and 1.4 mg/dL for females.
* Adequate Liver Function as defined as:
* Total bilirubin ≤ 3 times institutional upper limit of normal (ULN) for age
* AST(SGOT)/ALT(SGPT) ≤ 3 times institutional ULN
* Serum albumin ≥ 2g/dL
* Coagulation parameters: INR \<1.5 times ULN and aPTT \<1.5 times ULN unless patients are receiving therapeutic anticoagulation which affects these parameters
* Adequate Cardiac Function as defined as:
* Ejection fraction of ≥ 55% by echocardiogram
* Serum electrolytes (Sodium, Potassium, Chloride) within institutional limits of normal (patients can be on enteral supplementation)
3.12 Corticosteroids Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment, with a maximum dexamethasone dose of 2.5mg/m2/day.
3.13 Pregnancy Status Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
3.14 Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for at least 7 months after drug cessation in females of childbearing potential and for at least 4 months after drug cessation in males of child fathering potential.
3.15 Informed Consent The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.
Exclusion Criteria
1. Screening Criteria
1.1 Diagnosis Patient must have a diagnosis of primary high-grade CNS tumor (any histopathologic diagnosis that is WHO grade III-IV) or meningioma (any histologic grade) that is recurrent, progressive, or refractory. Note that patients with DIPG (based on radiographic/clinical diagnosis) who have undergone biopsy will be eligible with histologic diagnosis of grade II-IV infiltrating glioma. All tumors must have histologic verification either at the time of diagnosis or recurrence, except for patients meningioma who have not previously undergone biopsy or resection.
Note: Refractory disease is defined as the presence of persistent abnormality on conventional MRI that is further distinguished by histology (biopsy or sample of lesion) or advanced imaging, OR as determined by the treating physician and discussed with the primary investigator prior to enrollment.
1.2 Prior Therapy Patients must have recurred/progressed following prior standard therapy for their tumor. Note: Patients with meningioma, atypical meningioma, or anaplastic meningioma must have received at least surgical resection or radiation.
1.3 Screening Consent Participant/legal guardian is willing to sign a screening consent for \[68Ga\]Ga-DOTATATE PET imaging. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.
2. Eligibility Criteria
* Phase I Age Patient must be ≥ 4 and \<12 years of age at the time of enrollment. Disease Status: Patients who participate in the efficacy expansion cohort must have bi-dimensionally measurable disease, defined as at least one lesion that can be accurately measured in at least two dimensions Patients with measurable extraneural disease only are also eligible.
* Phase II Age Patient must be 12 to \</=39 years at the time of enrollment.
4.1 Confirmed bone marrow metastatic disease Patients with confirmed metastatic disease to bone marrow are ineligible.
4.2 Presence of bulky disease Patients with bulky disease on imaging as described below are ineligible. Treating physicians are encouraged to request a rapid central imaging review to confirm fulfillment of these criteria if there are questions or concerns.
Bulky disease is defined as:
* Tumor with evidence of clinically significant uncal herniation or midline shift.
* Tumor with diameter of \>5cm in one dimension on T2/FLAIR.
* Tumor that in the opinion of the site investigator shows significant mass effect in either the brain or spine.
Note that patients with metastatic or multi-focal disease (with exception of bone marrow) are eligible as long as no sites of disease meet above criteria for bulky disease.
4.3 Breast-feeding Nursing mothers are excluded from this study. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Lutathera.
4.4 Concurrent Illness
* Patients with a history of any other malignancy, except patients with a secondary brain tumor if the patient's prior malignancy has been in remission for at least 5 years from the end of treatment.
* Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
* Patients with type I diabetes.
4.5 Concomitant Medications
* Patients who are receiving any other anti-cancer or investigational drug therapy are ineligible.
* Prior or current treatment with 177Lu-DOTATATE/TOC or 90Y-DOTATATE/TOC.
4.6 Prisoners will be excluded from this study.
4.7 Inability to participate: Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits, obtain follow-up studies required to assess toxicity to therapy, or adhere to drug administration plan, other study procedures, and study restrictions.
5. Inclusion of Women and Minorities Both males and females of all races and ethnic groups are eligible for this study.
1.1 Diagnosis Patient must have a diagnosis of primary high-grade CNS tumor (any histopathologic diagnosis that is WHO grade III-IV) or meningioma (any histologic grade) that is recurrent, progressive, or refractory. Note that patients with DIPG (based on radiographic/clinical diagnosis) who have undergone biopsy will be eligible with histologic diagnosis of grade II-IV infiltrating glioma. All tumors must have histologic verification either at the time of diagnosis or recurrence, except for patients meningioma who have not previously undergone biopsy or resection.
Note: Refractory disease is defined as the presence of persistent abnormality on conventional MRI that is further distinguished by histology (biopsy or sample of lesion) or advanced imaging, OR as determined by the treating physician and discussed with the primary investigator prior to enrollment.
1.2 Prior Therapy Patients must have recurred/progressed following prior standard therapy for their tumor. Note: Patients with meningioma, atypical meningioma, or anaplastic meningioma must have received at least surgical resection or radiation.
1.3 Screening Consent Participant/legal guardian is willing to sign a screening consent for \[68Ga\]Ga-DOTATATE PET imaging. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.
2. Eligibility Criteria
* Phase I Age Patient must be ≥ 4 and \<12 years of age at the time of enrollment. Disease Status: Patients who participate in the efficacy expansion cohort must have bi-dimensionally measurable disease, defined as at least one lesion that can be accurately measured in at least two dimensions Patients with measurable extraneural disease only are also eligible.
* Phase II Age Patient must be 12 to \</=39 years at the time of enrollment.
4.1 Confirmed bone marrow metastatic disease Patients with confirmed metastatic disease to bone marrow are ineligible.
4.2 Presence of bulky disease Patients with bulky disease on imaging as described below are ineligible. Treating physicians are encouraged to request a rapid central imaging review to confirm fulfillment of these criteria if there are questions or concerns.
Bulky disease is defined as:
* Tumor with evidence of clinically significant uncal herniation or midline shift.
* Tumor with diameter of \>5cm in one dimension on T2/FLAIR.
* Tumor that in the opinion of the site investigator shows significant mass effect in either the brain or spine.
Note that patients with metastatic or multi-focal disease (with exception of bone marrow) are eligible as long as no sites of disease meet above criteria for bulky disease.
4.3 Breast-feeding Nursing mothers are excluded from this study. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Lutathera.
4.4 Concurrent Illness
* Patients with a history of any other malignancy, except patients with a secondary brain tumor if the patient's prior malignancy has been in remission for at least 5 years from the end of treatment.
* Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
* Patients with type I diabetes.
4.5 Concomitant Medications
* Patients who are receiving any other anti-cancer or investigational drug therapy are ineligible.
* Prior or current treatment with 177Lu-DOTATATE/TOC or 90Y-DOTATATE/TOC.
4.6 Prisoners will be excluded from this study.
4.7 Inability to participate: Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits, obtain follow-up studies required to assess toxicity to therapy, or adhere to drug administration plan, other study procedures, and study restrictions.
5. Inclusion of Women and Minorities Both males and females of all races and ethnic groups are eligible for this study.
Minimum Eligible Age
4 Years
Maximum Eligible Age
39 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nationwide Children's Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Margot Lazow, MD
Role: PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital Colorado
Aurora, Colorado, United States
Site Status
WITHDRAWN
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Site Status
RECRUITING
Nationwide Children's Hospital
Columbus, Ohio, United States
Site Status
RECRUITING
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rotteveel JJ, Colon EJ. Preliminary note: vertebral-Doppler sonography in near sudden infant death syndrome (NSIDS). Pediatr Radiol. 1985;15(2):95-7. doi: 10.1007/BF02388711.
Reference Type
BACKGROUND
Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013 Aug;34(3):228-52. doi: 10.1016/j.yfrne.2013.07.005. Epub 2013 Jul 18.
Reference Type
BACKGROUND
Khera DC, Herschman BR, Sosa F. Tetracycline-induced esophageal ulcers. Report of two cases. Postgrad Med. 1980 Oct;68(4):113, 115. doi: 10.1080/00325481.1980.11715564.
Reference Type
BACKGROUND
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. doi: 10.1007/s002590050034.
Reference Type
BACKGROUND
Vaidyanathan G, Affleck DJ, Zhao XG, Keir ST, Zalutsky MR. [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma. Curr Radiopharm. 2010;3(1):29-36. doi: 10.2174/1874471011003010029.
Reference Type
BACKGROUND
Hauser P, Hanzely Z, Mathe D, Szabo E, Barna G, Sebestyen A, Jeney A, Schuler D, Fekete G, Garami M. Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study. Pediatr Hematol Oncol. 2009 Jul-Aug;26(5):363-74. doi: 10.1080/08880010902973293.
Reference Type
BACKGROUND
Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res. 1994 Nov 15;54(22):5895-901.
Reference Type
BACKGROUND
Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007 Nov;20(11):1172-82. doi: 10.1038/modpathol.3800954. Epub 2007 Sep 14.
Reference Type
BACKGROUND
Fruhwald MC, O'Dorisio MS, Pietsch T, Reubi JC. High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Pediatr Res. 1999 May;45(5 Pt 1):697-708. doi: 10.1203/00006450-199905010-00016.
Reference Type
BACKGROUND
Remke M, Hering E, Gerber NU, Kool M, Sturm D, Rickert CH, Gerss J, Schulz S, Hielscher T, Hasselblatt M, Jeibmann A, Hans V, Ramaswamy V, Taylor MD, Pietsch T, Rutkowski S, Korshunov A, Monoranu CM, Fruhwald MC. Somatostatin receptor subtype 2 (sst(2)) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst. 2013 Aug;29(8):1253-62. doi: 10.1007/s00381-013-2142-4. Epub 2013 May 16.
Reference Type
BACKGROUND
Guyotat J, Champier J, Pierre GS, Jouvet A, Bret P, Brisson C, Belin MF, Signorelli F, Montange MF. Differential expression of somatostatin receptors in medulloblastoma. J Neurooncol. 2001 Jan;51(2):93-103. doi: 10.1023/a:1010624702443.
Reference Type
BACKGROUND
Johnson MD, O'Connell MJ, Silberstein H, Korones D. Differential expression of somatostatin receptors, P44/42 MAPK, and mTOR activation in medulloblastomas and primitive neuroectodermal tumors. Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):532-8. doi: 10.1097/PAI.0b013e3182813724.
Reference Type
BACKGROUND
Muller HL, Fruhwald MC, Scheubeck M, Rendl J, Warmuth-Metz M, Sorensen N, Kuhl J, Reubi JC. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurooncol. 1998 May;38(1):27-40. doi: 10.1023/a:1005961302340.
Reference Type
BACKGROUND
Fruhwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G, Paulus W, Kuhl J, Jurgens H, Schneider P, Muller HL. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res. 2004 May 1;10(9):2997-3006. doi: 10.1158/1078-0432.ccr-03-0083.
Reference Type
BACKGROUND
Feindt J, Becker I, Blomer U, Hugo HH, Mehdorn HM, Krisch B, Mentlein R. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem. 1995 Nov;65(5):1997-2005. doi: 10.1046/j.1471-4159.1995.65051997.x.
Reference Type
BACKGROUND
Held-Feindt J, Krisch B, Mentlein R. Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells. Brain Res Mol Brain Res. 1999 Jan 22;64(1):101-7. doi: 10.1016/s0169-328x(98)00312-x.
Reference Type
BACKGROUND
Kiviniemi A, Gardberg M, Kivinen K, Posti JP, Vuorinen V, Sipila J, Rahi M, Sankinen M, Minn H. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. Oncotarget. 2017 Jul 25;8(30):49123-49132. doi: 10.18632/oncotarget.17097.
Reference Type
BACKGROUND
Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathol Commun. 2018 Sep 7;6(1):89. doi: 10.1186/s40478-018-0594-1.
Reference Type
BACKGROUND
Cervera P, Videau C, Viollet C, Petrucci C, Lacombe J, Winsky-Sommerer R, Csaba Z, Helboe L, Daumas-Duport C, Reubi JC, Epelbaum J. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol. 2002 Jun;14(6):458-71. doi: 10.1046/j.1365-2826.2002.00801.x.
Reference Type
BACKGROUND
Lapa C, Linsenmann T, Luckerath K, Samnick S, Herrmann K, Stoffer C, Ernestus RI, Buck AK, Lohr M, Monoranu CM. Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy? PLoS One. 2015 Mar 25;10(3):e0122269. doi: 10.1371/journal.pone.0122269. eCollection 2015.
Reference Type
BACKGROUND
Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000 May;6(5):1865-74.
Reference Type
BACKGROUND
Savelli G, Muni A. Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT. Clin Nucl Med. 2015 Jul;40(7):e363-5. doi: 10.1097/RLU.0000000000000816.
Reference Type
BACKGROUND
Collamati F, Pepe A, Bellini F, Bocci V, Chiodi G, Cremonesi M, De Lucia E, Ferrari ME, Frallicciardi PM, Grana CM, Marafini M, Mattei I, Morganti S, Patera V, Piersanti L, Recchia L, Russomando A, Sarti A, Sciubba A, Senzacqua M, Solfaroli Camillocci E, Voena C, Pinci D, Faccini R. Toward radioguided surgery with beta- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma. J Nucl Med. 2015 Jan;56(1):3-8. doi: 10.2967/jnumed.114.145995. Epub 2014 Dec 11.
Reference Type
BACKGROUND
Khanna G, O'Dorisio MS, Menda Y, Glasier C, Deyoung B, Smith BJ, Graham M, Juweid M. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatr Blood Cancer. 2008 Mar;50(3):561-6. doi: 10.1002/pbc.21194.
Reference Type
BACKGROUND
Marincek N, Radojewski P, Dumont RA, Brunner P, Muller-Brand J, Maecke HR, Briel M, Walter MA. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015 Feb;56(2):171-6. doi: 10.2967/jnumed.114.147256. Epub 2015 Jan 15.
Reference Type
BACKGROUND
de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001 Jun 1;92(5):628-33. doi: 10.1002/1097-0215(20010601)92:53.0.co;2-l.
Reference Type
BACKGROUND
Galvis L, Gonzalez D, Bonilla C. Relapsed High-Risk Medulloblastoma: Stable Disease after Two Years of Treatment with Somatostatin Analog - Case Report. Cureus. 2016 Jan 4;8(1):e446. doi: 10.7759/cureus.446.
Reference Type
BACKGROUND
Glas M, Hennemann B, Hirschmann B, Marienhagen J, Schmidt-Wolf I, Herrlinger U, Bogdahn U, Hau P. Complete response after treatment with a somatostatin analogue in an adult patient with recurrent medulloblastoma. Acta Oncol. 2008;47(3):479-80. doi: 10.1080/02841860701678795. Epub 2007 Oct 12. No abstract available.
Reference Type
BACKGROUND
Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008 Jan 1;13:822-40. doi: 10.2741/2722.
Reference Type
BACKGROUND
Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med. 2010 Oct;51(10):1524-31. doi: 10.2967/jnumed.110.075226. Epub 2010 Sep 16.
Reference Type
BACKGROUND
Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998 May 29;76(5):620-7. doi: 10.1002/(sici)1097-0215(19980529)76:53.0.co;2-s.
Reference Type
BACKGROUND
Hosono M, Ikebuchi H, Nakamura Y, Nakamura N, Yamada T, Yanagida S, Kitaoka A, Kojima K, Sugano H, Kinuya S, Inoue T, Hatazawa J. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Ann Nucl Med. 2018 Apr;32(3):217-235. doi: 10.1007/s12149-018-1230-7. Epub 2018 Jan 15.
Reference Type
BACKGROUND
Hamiditabar M, Ali M, Roys J, Wolin EM, O'Dorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med. 2017 Jun;42(6):436-443. doi: 10.1097/RLU.0000000000001629.
Reference Type
BACKGROUND
John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherubl H, Boese-Landgraf J, Neuhaus P, Ziske C, Molling K, Riecken EO, Reubi JC, Wiedenmann B. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut. 1996 Jan;38(1):33-9. doi: 10.1136/gut.38.1.33.
Reference Type
BACKGROUND
Diakatou E, Alexandraki KI, Tsolakis AV, Kontogeorgos G, Chatzellis E, Leonti A, Kaltsas GA. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clin Endocrinol (Oxf). 2015 Sep;83(3):420-8. doi: 10.1111/cen.12775. Epub 2015 Apr 24.
Reference Type
BACKGROUND
Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):48-52. doi: 10.1007/s00259-008-0944-5. Epub 2008 Sep 20.
Reference Type
BACKGROUND
Korner M, Waser B, Schonbrunn A, Perren A, Reubi JC. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol. 2012 Feb;36(2):242-52. doi: 10.1097/PAS.0b013e31823d07f3.
Reference Type
BACKGROUND
Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016 Nov;45(10):1386-1393. doi: 10.1097/MPA.0000000000000700.
Reference Type
BACKGROUND
Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW, Schonbrunn A. Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J Clin Endocrinol Metab. 1999 Aug;84(8):2942-50. doi: 10.1210/jcem.84.8.5878.
Reference Type
BACKGROUND
Mehta S, de Reuver PR, Gill P, Andrici J, D'Urso L, Mittal A, Pavlakis N, Clarke S, Samra JS, Gill AJ. Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine (Baltimore). 2015 Oct;94(40):e1281. doi: 10.1097/MD.0000000000001281.
Reference Type
BACKGROUND
Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M, Koizumi W. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013 Dec 1;119(23):4094-102. doi: 10.1002/cncr.28341. Epub 2013 Sep 10.
Reference Type
BACKGROUND
Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A, Delle Fave G. Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology. 2009;89(2):223-30. doi: 10.1159/000167796. Epub 2008 Oct 31.
Reference Type
BACKGROUND
Moertel CL, Reubi JC, Scheithauer BS, Schaid DJ, Kvols LK. Expression of somatostatin receptors in childhood neuroblastoma. Am J Clin Pathol. 1994 Dec;102(6):752-6. doi: 10.1093/ajcp/102.6.752.
Reference Type
BACKGROUND
Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, Cumming P, Bartenstein P, Tiling R, Hacker M. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010 Sep;51(9):1349-56. doi: 10.2967/jnumed.110.075002. Epub 2010 Aug 18.
Reference Type
BACKGROUND
Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002 Apr;32(2):84-91. doi: 10.1053/snuc.2002.31022.
Reference Type
BACKGROUND
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005 Apr 20;23(12):2754-62. doi: 10.1200/JCO.2005.08.066.
Reference Type
BACKGROUND
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015 Mar-Apr;35(2):500-16. doi: 10.1148/rg.352140164.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FD-R-0532-01
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CONNECT2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of 177Lu-PSMA-617 in People With Gliomas
NCT07223034
RECRUITING
PHASE1
Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
NCT02458339
COMPLETED
PHASE1
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
NCT03598244
ACTIVE_NOT_RECRUITING
PHASE1
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728
ACTIVE_NOT_RECRUITING
PHASE1
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
NCT06955169
RECRUITING
PHASE2
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
NCT02014545
WITHDRAWN
PHASE2
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
NCT02609737
COMPLETED
NA
Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease
NCT01438021
WITHDRAWN
NA
Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
NCT06614205
COMPLETED
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
NCT00527410
TERMINATED
PHASE1
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
NCT00679354
COMPLETED
PHASE2
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
NCT02359565
ACTIVE_NOT_RECRUITING
PHASE1
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
NCT00463008
COMPLETED
NA
High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma
NCT00283556
COMPLETED
PHASE1/PHASE2
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
NCT02858895
COMPLETED
PHASE2
Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas
NCT00822887
COMPLETED
PHASE1
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
NCT06466798
WITHDRAWN
PHASE1
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
NCT05222802
ACTIVE_NOT_RECRUITING
PHASE1
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
NCT00509301
COMPLETED
PHASE1
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
NCT01089101
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
NCT01222754
COMPLETED
PHASE1
A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
NCT03028246
RECRUITING
NA
Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
NCT01600742
TERMINATED
PHASE2
Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases
NCT01410370
UNKNOWN
PHASE2